Bionano to Present at the Canaccord Genuity 43rd Annual Growth Conference
July 27 2023 - 8:00AM
Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that
Erik Holmlin, Ph.D., Bionano’s president and chief executive
officer will present at the Canaccord Genuity 43rd Annual Growth
Conference on August 10, 2023.
Conference & Webcast Details
Date: |
Thursday, August 10th, 2023 |
Time: |
11:30 a.m. to 11:55 a.m. ET |
Presenter: |
Erik Holmlin, Ph.D., CEO of Bionano |
Webcast: |
https://wsw.com/webcast/canaccord89/bngo/2447258 |
A replay / recording of the session will be available following
the conference through the Bionano website
at https://ir.bionano.com/ for at least 30 days.
About the Canaccord Genuity 43rd Annual Growth
Conference
This annual event brings together institutional investors from
across the globe with some of the best and most promising growth
companies in Canaccord Genuity’s core sectors - Technology,
Healthcare & Life Sciences, Sustainability, Industrials, and
Consumer & Retail.
About Bionano
Bionano is a provider of genome analysis solutions that can
enable researchers and clinicians to reveal answers to challenging
questions in biology and medicine. The Company’s mission is to
transform the way the world sees the genome through OGM solutions,
diagnostic services and software. The Company offers OGM solutions
for applications across basic, translational and clinical research.
Through its Lineagen, Inc. d/b/a Bionano Laboratories business, the
Company also provides diagnostic testing for patients with clinical
presentations consistent with autism spectrum disorder and other
neurodevelopmental disabilities. The Company also offers an
industry-leading, platform-agnostic software solution, which
integrates next-generation sequencing and microarray data designed
to provide analysis, visualization, interpretation and reporting of
copy number variants, single-nucleotide variants and absence of
heterozygosity across the genome in one consolidated view. The
Company additionally offers nucleic acid extraction and
purification solutions using proprietary isotachophoresis (ITP)
technology. For more information, visit www.bionano.com,
www.bionanolaboratories.com or www.purigenbio.com.
CONTACTS
Company Contact:Erik Holmlin, CEOBionano
Genomics, Inc.+1 (858) 888-7610eholmlin@bionano.com
Investor Relations:David HolmesGilmartin
Group+1 (858) 888-7625IR@bionano.com
Bionano Genomics (NASDAQ:BNGO)
Historical Stock Chart
From Jun 2024 to Jul 2024
Bionano Genomics (NASDAQ:BNGO)
Historical Stock Chart
From Jul 2023 to Jul 2024